Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
03692 HANSOH PHARMA
RTNominal unchange15.480 0.000 (0.000%)
Others

16/07/2019 15:08

[I-bank focus]Morgan starts Hansoh Pharma (03692) at HK$29

[ET Net News Agency, 16 July 2019] Morgan Stanley initiated coverage on Hansoh
Pharmaceutical (03692) with an "overweight" rating and a target price of HK$29.
The research house sees strong catalysts ahead for the giant pharma company - the launch
of 30+ drugs in 2019-20, including 4 Class 1.1 drugs and 8 first-to-market (FTM) generics,
driving 36% and 28.7% earnings growth.
Morgan said Hansoh is a leading company, by sales revenue, for drugs related to the
central nervous system (CNS), oncology, infectious diseases, and diabetes, which,
combined, accounted for >60% of China drug sales in 2018. Hansoh has a commanding lead in
CNS and a strong position in oncology, both underpinned by strong demand from an aging
population.
It added that Hansoh is a rare drug company with minimal exposure to adjuvant drug
sales; this makes it more resistant to continued pressure from stringent government
control of insurance reimbursement and the drug sales ratio on hospital revenue.
Morgan modeled revenue and earnings CAGRs of 18.3% and 29% from 2018 to 2021. These
numbers are underpinned by robust growth forecasts of Hansoh's oncology, anti-infectives,
diabetes, and CNS portfolios, as well as margin expansion. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.